Nuvilex, Inc. Will Enter Phase III Trials With Advantages Using Cell Encapsulation
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 07/09/13 -- When Nuvilex, Inc. (OTCQB: NVLX) enters its pivotal Phase III clinical trial using its cell encapsulation technology combined with the anti-cancer drug ifosfamide for the treatment of late stage, inoperable pancreatic cancer, the company will do so with a number of distinct advantages. The encapsulated cells capable of converting ifosfamide into its "cancer-killing" form could very well prove to be the "magic bullet" that catapults Nuvilex's treatment to the standard therapy for the disease.
Nuvilex's advantages all start with the encapsulation process itself. The company's unique, proprietary, cell encapsulation technology forms a "platform" upon which treatments for many serious, debilitating, and even fatal diseases may be built; these diseases include, but are not limited to, different types of cancer and diabetes.
The "capsules," in the cell encapsulation process, are made principally of cellulose and, once formed, act as "mini-factories" and can carry out specific functions like activating cancer drugs. The porous nature of the capsules allow nutrients to enter and support the health of the encapsulated cells, and at the same time, the capsules are porous enough to permit activated drugs or other biological substances to leave and provide "beneficial factors" to their surrounding environment. The cells cannot leave the capsules nor can other cells, like those of the immune system, enter the capsules.
Because Nuvilex's cell encapsulation process is a true platform technology, it has many possible uses versus other companies' technologies that are often aimed at the treatment of a single type of cancer or a single disease. Nuvilex also has advantages over other companies using cell encapsulation methods when it comes to using different types of cells. Those companies may need to make major modifications to the encapsulation process with each cell type they use.
Continue reading this article at .
About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles while building a library of Research for Investors to become better informed on small cap companies. For more information:
Contact:
Stock Market Media Group
(646) 397-4020
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.07.2013 - 12:30 Uhr
Sprache: Deutsch
News-ID 276620
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 187 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nuvilex, Inc. Will Enter Phase III Trials With Advantages Using Cell Encapsulation"
steht unter der journalistisch-redaktionellen Verantwortung von
Nuvilex, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
